Laurent Verkoczy1, Marilyn Diaz. 1. aDuke Human Vaccine Institute, Duke University Medical Center, Durham bNational Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA.
Abstract
PURPOSE OF REVIEW: This review discusses progress in understanding the impact of immune tolerance on inducing broadly neutralizing antibodies (bnAbs), and how such knowledge can be incorporated into novel immunization approaches. RECENT FINDINGS: Over 120 bnAbs have now been isolated, all of which bear unusual features associated with host tolerance controls, but paradoxically may also be required for their function. Evidence that poly/autoreactivity of membrane proximal external region bnAbs can invoke such controls has been demonstrated by knock-in technology, highlighting its potential for studying the impact of tolerance in the generation of bnAb lineages to distinct HIV-1 envelope targets. The requirement for extensive affinity maturation in developing neutralization breadth/potency during infection is being examined, and similar studies in the setting of immunization will be aided by testing novel vaccine approaches in knock-in models that either selectively express reverted V(D)J rearrangements, or unrearranged germline segments, from which bnAb lineages originate. SUMMARY: It is increasingly apparent that immune tolerance, sometimes invoked by self-reactivity that overlaps with bnAb epitope specificity, adds to a formidable set of roadblocks impeding bnAb induction. The path to an effective HIV-1 vaccine may thus benefit from a deeper understanding of host controls, including categorizing those that are unique or common at distinct bnAb targets, and ranking those most feasible to overcome by immunization. Ultimately, such emerging information will be critical to incorporate into new vaccine approaches that can be tested in human trials.
PURPOSE OF REVIEW: This review discusses progress in understanding the impact of immune tolerance on inducing broadly neutralizing antibodies (bnAbs), and how such knowledge can be incorporated into novel immunization approaches. RECENT FINDINGS: Over 120 bnAbs have now been isolated, all of which bear unusual features associated with host tolerance controls, but paradoxically may also be required for their function. Evidence that poly/autoreactivity of membrane proximal external region bnAbs can invoke such controls has been demonstrated by knock-in technology, highlighting its potential for studying the impact of tolerance in the generation of bnAb lineages to distinct HIV-1 envelope targets. The requirement for extensive affinity maturation in developing neutralization breadth/potency during infection is being examined, and similar studies in the setting of immunization will be aided by testing novel vaccine approaches in knock-in models that either selectively express reverted V(D)J rearrangements, or unrearranged germline segments, from which bnAb lineages originate. SUMMARY: It is increasingly apparent that immune tolerance, sometimes invoked by self-reactivity that overlaps with bnAb epitope specificity, adds to a formidable set of roadblocks impeding bnAb induction. The path to an effective HIV-1 vaccine may thus benefit from a deeper understanding of host controls, including categorizing those that are unique or common at distinct bnAb targets, and ranking those most feasible to overcome by immunization. Ultimately, such emerging information will be critical to incorporate into new vaccine approaches that can be tested in human trials.
Authors: Gilad Ofek; Krisha McKee; Yongping Yang; Zhi-Yong Yang; Jeff Skinner; F Javier Guenaga; Richard Wyatt; Michael B Zwick; Gary J Nabel; John R Mascola; Peter D Kwong Journal: J Virol Date: 2009-12-30 Impact factor: 5.103
Authors: Florian Klein; Ron Diskin; Johannes F Scheid; Christian Gaebler; Hugo Mouquet; Ivelin S Georgiev; Marie Pancera; Tongqing Zhou; Reha-Baris Incesu; Brooks Zhongzheng Fu; Priyanthi N P Gnanapragasam; Thiago Y Oliveira; Michael S Seaman; Peter D Kwong; Pamela J Bjorkman; Michel C Nussenzweig Journal: Cell Date: 2013-03-28 Impact factor: 41.582
Authors: Ivelin S Georgiev; Rebecca S Rudicell; Kevin O Saunders; Wei Shi; Tatsiana Kirys; Krisha McKee; Sijy O'Dell; Gwo-Yu Chuang; Zhi-Yong Yang; Gilad Ofek; Mark Connors; John R Mascola; Gary J Nabel; Peter D Kwong Journal: J Immunol Date: 2014-01-03 Impact factor: 5.422
Authors: Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw Journal: Nature Date: 2003-03-20 Impact factor: 49.962
Authors: Penny L Moore; Elin S Gray; C Kurt Wibmer; Jinal N Bhiman; Molati Nonyane; Daniel J Sheward; Tandile Hermanus; Shringkhala Bajimaya; Nancy L Tumba; Melissa-Rose Abrahams; Bronwen E Lambson; Nthabeleng Ranchobe; Lihua Ping; Nobubelo Ngandu; Quarraisha Abdool Karim; Salim S Abdool Karim; Ronald I Swanstrom; Michael S Seaman; Carolyn Williamson; Lynn Morris Journal: Nat Med Date: 2012-10-21 Impact factor: 53.440
Authors: S Moses Dennison; Laura L Sutherland; Frederick H Jaeger; Kara M Anasti; Robert Parks; Shelley Stewart; Cindy Bowman; Shi-Mao Xia; Ruijun Zhang; Xiaoying Shen; Richard M Scearce; Gilad Ofek; Yongping Yang; Peter D Kwong; Sampa Santra; Hua-Xin Liao; Georgia Tomaras; Norman L Letvin; Bing Chen; S Munir Alam; Barton F Haynes Journal: PLoS One Date: 2011-11-30 Impact factor: 3.240
Authors: Mattias N E Forsell; Krisha McKee; Yu Feng; John R Mascola; Richard T Wyatt Journal: AIDS Res Hum Retroviruses Date: 2014-11 Impact factor: 2.205
Authors: Stella J Berendam; Tiffany M Styles; Rama R Amara; Genevieve G Fouda; Papa K Morgan-Asiedu; DeAnna Tenney; Amit Kumar; Veronica Obregon-Perko; Katharine J Bar; Kevin O Saunders; Sampa Santra; Kristina De Paris; Georgia D Tomaras; Ann Chahroudi; Sallie R Permar Journal: J Virol Date: 2021-01-13 Impact factor: 5.103
Authors: Vincent J Venditto; Lindsay Wieczorek; Sebastian Molnar; Fernando Teque; Gary Landucci; Douglas S Watson; Donald Forthal; Victoria R Polonis; Jay A Levy; Francis C Szoka Journal: Clin Vaccine Immunol Date: 2014-05-28